<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30167089</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1949-2553</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>9</Volume>                    <Issue>60</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>03</Day>                    </PubDate>                </JournalIssue>                <Title>Oncotarget</Title>                <ISOAbbreviation>Oncotarget</ISOAbbreviation>            </Journal>            <ArticleTitle>A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.</ArticleTitle>            <Pagination>                <MedlinePgn>31709-31718</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.25854</ELocationID>            <Abstract>                <AbstractText>Phosphatidylinositol 3-kinase (PI3K) pathway activation is associated with resistance to paclitaxel in solid tumors. We assessed the safety and activity of alpelisib, an oral, selective PI3K p110Î± inhibitor, plus paclitaxel in patients with advanced solid tumors. This Phase Ib, multicenter, open-label, dose-finding study, with a planned dose-expansion phase of alpelisib once daily (QD) plus fixed-dose paclitaxel, recruited patients with advanced solid tumors. For the dose-finding phase, the primary objective was determination of maximum tolerated and/or recommended Phase II dose of alpelisib plus paclitaxel, and the secondary objectives included the assessment of safety for this combination. From March 2014 to August 2016, 19 patients with advanced solid tumors were treated with alpelisib QD (300 mg, n=6; 250 mg, n=4; 150 mg, n=9) plus paclitaxel (80 mg/m<sup>2</sup>, per standard of care). During dose finding, five of 12 (41.7%) evaluable patients for MTD determination experienced dose-limiting toxicities: alpelisib 300 mg, Grade 2 hyperglycemia (n=1); alpelisib 250 mg, Grade 2 hyperglycemia (n=1), Grade 4 hyperglycemia and Grade 3 acute kidney injury (n=1); and alpelisib 150 mg, Grade 2 hyperglycemia (n=1) and Grade 4 leukopenia (n=1). The MTD of alpelisib when administered with paclitaxel was 150 mg QD. Most frequent all-grade AEs were diarrhea (73.7%; Grade 3/4 10.5%) and hyperglycemia (57.9%; Grade 3/4 31.6%). The planned dose-expansion phase was not initiated. Alpelisib plus paclitaxel has a challenging safety profile in patients with advanced solid tumors. This study was closed following the completion of the dose-finding phase.</AbstractText>                <AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT02051751.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rodon</LastName>                    <ForeName>Jordi</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Centro Cellex, 08035, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Curigliano</LastName>                    <ForeName>Giuseppe</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Early Drug Development for Innovative Therapies, Department of Hematology and Oncology, University of Milano, Istituto Europeo di Oncologia, 20141, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Delord</LastName>                    <ForeName>Jean-Pierre</ForeName>                    <Initials>JP</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Research Unit, Institut Claudius Regaud, 31052, Toulouse, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Harb</LastName>                    <ForeName>Wael</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Horizon Oncology Center, 47905, Lafayette, IN, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Azaro</LastName>                    <ForeName>Analia</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Centro Cellex, 08035, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Han</LastName>                    <ForeName>Yu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Novartis Pharmaceuticals Corporation, 07936, East Hanover, NJ, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wilke</LastName>                    <ForeName>Celine</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Novartis Pharma AG, Postfach, CH-4002, Basel, Switzerland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Donnet</LastName>                    <ForeName>Valerie</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Novartis Pharma S.A.S., 92506, Rueil-Malmaison, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sellami</LastName>                    <ForeName>Dalila</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Novartis Pharmaceuticals Corporation, 07936, East Hanover, NJ, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Beck</LastName>                    <ForeName>Thaddeus</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Highlands Oncology Group, 72703, Fayetteville, AR, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <DataBankList CompleteYN="Y">                <DataBank>                    <DataBankName>ClinicalTrials.gov</DataBankName>                    <AccessionNumberList>                        <AccessionNumber>NCT02051751</AccessionNumber>                    </AccessionNumberList>                </DataBank>            </DataBankList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncotarget</MedlineTA>            <NlmUniqueID>101532965</NlmUniqueID>            <ISSNLinking>1949-2553</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2001 Nov 15;19(22):4216-23</RefSource>                <PMID Version="1">11709565</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biochem. 2015 Jul;116(7):1341-9</RefSource>                <PMID Version="1">25640606</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2005 Apr 15;11(8):2875-8</RefSource>                <PMID Version="1">15837735</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Discov. 2013 Jul;3(7):761-9</RefSource>                <PMID Version="1">23619167</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2003 Oct 20;22(47):7280-95</RefSource>                <PMID Version="1">14576838</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Feb 1;30(4):362-71</RefSource>                <PMID Version="1">22184370</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Drug Discov. 2009 Aug;8(8):627-44</RefSource>                <PMID Version="1">19644473</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Jul 18;487(7407):330-7</RefSource>                <PMID Version="1">22810696</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2012 Feb;11(2):317-28</RefSource>                <PMID Version="1">22188813</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Oct 4;490(7418):61-70</RefSource>                <PMID Version="1">23000897</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2014 May;13(5):1117-29</RefSource>                <PMID Version="1">24608574</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2018 May 1;36(13):1291-1299</RefSource>                <PMID Version="1">29401002</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2002 Feb 15;62(4):1087-92</RefSource>                <PMID Version="1">11861387</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Aug 10;30(23):2919-28</RefSource>                <PMID Version="1">22778315</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Jun 20;486(7403):405-9</RefSource>                <PMID Version="1">22722202</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Stat Med. 2008 Jun 15;27(13):2420-39</RefSource>                <PMID Version="1">18344187</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2013 Sep;30(3):1113-8</RefSource>                <PMID Version="1">23807572</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">PIK3CA protein</Keyword>            <Keyword MajorTopicYN="N">breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">chemotherapy</Keyword>            <Keyword MajorTopicYN="N">drug resistance</Keyword>            <Keyword MajorTopicYN="N">human</Keyword>        </KeywordList>        <CoiStatement>CONFLICTS OF INTEREST JR reports personal fees for advisory boards from Novartis, Lily, Orion, Servier, and Peptomyc; and grant funding from Bayer and Novartis. YH, CW, VD and DS are employees of Novartis Pharmaceuticals Corporation. CW and DS also report stock ownership from Novartis Pharmaceuticals Corporation. GC, J-P D, WH, AA, and TB declare no competing interest.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30167089</ArticleId>            <ArticleId IdType="doi">10.18632/oncotarget.25854</ArticleId>            <ArticleId IdType="pii">25854</ArticleId>            <ArticleId IdType="pmc">PMC6114962</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>